NZ605486A - Spiro-cyclic amine derivatives as s1p modulators - Google Patents
Spiro-cyclic amine derivatives as s1p modulatorsInfo
- Publication number
- NZ605486A NZ605486A NZ605486A NZ60548611A NZ605486A NZ 605486 A NZ605486 A NZ 605486A NZ 605486 A NZ605486 A NZ 605486A NZ 60548611 A NZ60548611 A NZ 60548611A NZ 605486 A NZ605486 A NZ 605486A
- Authority
- NZ
- New Zealand
- Prior art keywords
- disorder
- spiro
- cognitive
- disease
- modulators
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 abstract 1
- 208000024571 Pick disease Diseases 0.000 abstract 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 230000007000 age related cognitive decline Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36278210P | 2010-07-09 | 2010-07-09 | |
| EP10169104 | 2010-07-09 | ||
| US201161444186P | 2011-02-18 | 2011-02-18 | |
| EP11154961 | 2011-02-18 | ||
| PCT/EP2011/061599 WO2012004378A1 (en) | 2010-07-09 | 2011-07-08 | Spiro-cyclic amine derivatives as s1p modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ605486A true NZ605486A (en) | 2014-08-29 |
Family
ID=44315247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ605486A NZ605486A (en) | 2010-07-09 | 2011-07-08 | Spiro-cyclic amine derivatives as s1p modulators |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10179791B2 (es) |
| EP (2) | EP2590955B9 (es) |
| JP (1) | JP5922115B2 (es) |
| KR (1) | KR101889695B1 (es) |
| CN (1) | CN103097364B (es) |
| AR (1) | AR082135A1 (es) |
| AU (1) | AU2011275760B2 (es) |
| BR (1) | BR112013000629B1 (es) |
| CA (1) | CA2804143C (es) |
| DK (1) | DK2590955T3 (es) |
| ES (1) | ES2606137T3 (es) |
| HK (1) | HK1184153A1 (es) |
| IL (1) | IL224049B (es) |
| MX (1) | MX347423B (es) |
| NZ (1) | NZ605486A (es) |
| PL (1) | PL2590955T3 (es) |
| PT (1) | PT2590955T (es) |
| RU (2) | RU2602800C2 (es) |
| SG (1) | SG186926A1 (es) |
| TW (2) | TW201643169A (es) |
| UY (1) | UY33497A (es) |
| WO (1) | WO2012004378A1 (es) |
| ZA (1) | ZA201300153B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| USRE48301E1 (en) | 2010-07-09 | 2020-11-10 | Abbvie B.V. | Fused heterocyclic derivatives as S1P modulators |
| CN102250035A (zh) * | 2011-06-10 | 2011-11-23 | 北京富卡生物技术有限公司 | 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途 |
| US8642585B2 (en) * | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| US8809376B2 (en) | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| WO2014086712A1 (en) | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
| KR101598612B1 (ko) * | 2013-08-29 | 2016-02-26 | 재단법인 아산사회복지재단 | Dpp-4 억제제를 포함하는 혈관 또는 심장판막 석회화의 예방 또는 치료용 조성물 |
| CN107253903B (zh) * | 2016-06-20 | 2020-11-24 | 北京海步医药科技股份有限公司 | 制备一种能够结合s1p受体化合物及其中间体的方法 |
| EP3535244A1 (en) | 2016-11-02 | 2019-09-11 | Abbvie Deutschland GmbH & Co. KG | Spiro-compounds as s1p modulators |
| JP7023969B2 (ja) | 2017-01-26 | 2022-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| CN110312714B (zh) | 2017-01-26 | 2022-12-09 | 勃林格殷格翰国际有限公司 | 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| WO2018138028A1 (en) | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7049353B2 (ja) | 2017-02-08 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 |
| EP3590929B1 (en) * | 2017-02-28 | 2021-09-15 | Medshine Discovery Inc. | Spiro compound and use thereof |
| CN110092774B (zh) * | 2018-01-29 | 2022-04-08 | 中国科学院上海药物研究所 | 芳香丙酸类衍生物、及其制备方法和用途 |
| US11458124B2 (en) | 2018-07-12 | 2022-10-04 | UCBBiopharma Srl | Spirocyclic indane analogues as IL-17 modulators |
| AU2020373047A1 (en) | 2019-10-31 | 2022-05-19 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
| WO2022117553A1 (en) * | 2020-12-01 | 2022-06-09 | AbbVie Deutschland GmbH & Co. KG | Spiro-cyclic amine derivatives as s1p modulators |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3962259A (en) | 1973-12-12 | 1976-06-08 | American Hoechst Corporation | 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof |
| US3980787A (en) * | 1975-08-25 | 1976-09-14 | American Hoechst Corporation | 3-Phenylspiro[isobenzofuran-1,4'-piperidine]sulfenamides and derivatives |
| SU1069387A1 (ru) | 1982-07-01 | 1985-11-30 | Институт физико-органической химии и углехимии АН УССР | Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием |
| GB2228432A (en) | 1989-01-13 | 1990-08-29 | Grayston Central Services | Multi-role machine for heating and coating pipe welds. |
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| JPH03206042A (ja) | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
| JP2681589B2 (ja) | 1992-12-28 | 1997-11-26 | 日揮株式会社 | 配管溶接継手の熱処理方法 |
| JPH072848A (ja) | 1993-04-23 | 1995-01-06 | Sankyo Co Ltd | モルホリンおよびチオモルホリン誘導体 |
| GB9522845D0 (en) * | 1995-11-08 | 1996-01-10 | Smithkline Beecham Plc | Novel compounds |
| JP3822680B2 (ja) | 1996-08-30 | 2006-09-20 | 新日本製鐵株式会社 | 誘導加熱された接合部の冷却方法および冷却装置 |
| TWI243173B (en) * | 1999-11-17 | 2005-11-11 | Akzo Nobel Nv | Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| RU2275371C2 (ru) | 2000-04-21 | 2006-04-27 | Шионоги Энд Ко., Лтд. | Производные оксадиазола, обладающие противоопухолевым действием, лекарственное средство, их содержащее, и способ лечения |
| FR2822727A1 (fr) | 2001-04-03 | 2002-10-04 | Gesal Ind | Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement |
| JP3649223B2 (ja) | 2003-01-08 | 2005-05-18 | 株式会社日立製作所 | 配管系の熱処理方法および熱処理装置 |
| JP4648899B2 (ja) | 2003-06-12 | 2011-03-09 | ビーティージー・インターナショナル・リミテッド | 神経賦活性化合物としての環式ヒドロキシルアミン |
| EP1663188B1 (en) | 2003-09-12 | 2016-08-10 | Newron Sweden AB | Treatment of disorders of the nervous system |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| JP2007516298A (ja) | 2003-12-23 | 2007-06-21 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物 |
| GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| JP2007530656A (ja) * | 2004-03-29 | 2007-11-01 | ファイザー株式会社 | ＯＲＬ１受容体拮抗薬としてのαアリールまたはヘテロアリールメチルβピペリジノプロパンアミド化合物 |
| GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| CA2564994A1 (en) | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| JP4491334B2 (ja) | 2004-12-01 | 2010-06-30 | 日立Ｇｅニュークリア・エナジー株式会社 | 配管の熱処理方法および装置 |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| JP4599250B2 (ja) | 2005-08-10 | 2010-12-15 | 株式会社東芝 | 高周波誘導加熱時外面温度制御方法および当該制御装置 |
| JP2007063642A (ja) | 2005-09-01 | 2007-03-15 | Hitachi Ltd | 残留応力改善方法と高周波誘導加熱用コイル |
| CA2629018C (en) * | 2005-11-10 | 2013-12-31 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
| WO2007057775A1 (en) | 2005-11-21 | 2007-05-24 | Pfizer Limited | Spiropiperidine derivatives |
| RU2008130094A (ru) * | 2005-12-22 | 2010-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы мускариновых рецепторов |
| EP1981497A2 (en) | 2006-01-27 | 2008-10-22 | F.Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
| ES2338716T3 (es) | 2006-01-27 | 2010-05-11 | F.Hoffmann-La Roche Ag | Uso de derivados de 4-imidazol para trastornos del snc. |
| JP2009528363A (ja) | 2006-02-28 | 2009-08-06 | ヘリコン セラピューティクス，インコーポレイテッド | Ｐｄｅ４インヒビターとしての治療用ピペラジン |
| WO2007109334A2 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | Sip receptor modulating compounds and use thereof |
| GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
| EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| JP2010502675A (ja) | 2006-09-08 | 2010-01-28 | ノバルティス アクチエンゲゼルシャフト | リンパ球相互作用が介在する疾患または障害を処置するために有用なｎ−ビアリール（ヘテロ）アリールスルホンアミド誘導体 |
| BRPI0720478A2 (pt) * | 2006-12-21 | 2014-01-14 | Abbott Laboratoires | Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato |
| WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| MX2009011421A (es) | 2007-04-23 | 2009-12-15 | Novartis Ag | Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p. |
| WO2009084501A1 (ja) | 2007-12-27 | 2009-07-09 | Asahi Kasei Pharma Corporation | スルタム誘導体 |
| CA2710474A1 (en) | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| UA100877C2 (ru) | 2008-01-30 | 2013-02-11 | Сефалон, Інк. | Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3) |
| WO2009097567A1 (en) * | 2008-01-30 | 2009-08-06 | Cephalon, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| US20090321144A1 (en) | 2008-06-30 | 2009-12-31 | Wyble Kevin J | Protecting an element from excessive surface wear by localized hardening |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| US9051275B2 (en) | 2010-02-04 | 2015-06-09 | Laboratories Del Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| CN101812058B (zh) | 2010-04-13 | 2012-03-21 | 湖南大学 | 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用 |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| US10179971B2 (en) | 2014-03-21 | 2019-01-15 | Iogen Energy Corporation | Method for processing a cellulosic feedstock at high consistency |
| BR112022008137A2 (pt) | 2019-10-31 | 2022-07-19 | Escape Bio Inc | Processos para preparar um modulador de receptor s1p |
| AU2020373047A1 (en) | 2019-10-31 | 2022-05-19 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
-
2011
- 2011-07-07 TW TW105117687A patent/TW201643169A/zh unknown
- 2011-07-07 TW TW100124108A patent/TWI543984B/zh active
- 2011-07-08 AU AU2011275760A patent/AU2011275760B2/en active Active
- 2011-07-08 EP EP11730314.9A patent/EP2590955B9/en active Active
- 2011-07-08 CN CN201180033970.6A patent/CN103097364B/zh active Active
- 2011-07-08 ES ES11730314.9T patent/ES2606137T3/es active Active
- 2011-07-08 JP JP2013517401A patent/JP5922115B2/ja active Active
- 2011-07-08 AR ARP110102454A patent/AR082135A1/es unknown
- 2011-07-08 US US13/808,903 patent/US10179791B2/en active Active
- 2011-07-08 BR BR112013000629-3A patent/BR112013000629B1/pt active IP Right Grant
- 2011-07-08 RU RU2013105490/04A patent/RU2602800C2/ru active
- 2011-07-08 CA CA2804143A patent/CA2804143C/en active Active
- 2011-07-08 WO PCT/EP2011/061599 patent/WO2012004378A1/en active Application Filing
- 2011-07-08 DK DK11730314.9T patent/DK2590955T3/en active
- 2011-07-08 MX MX2013000362A patent/MX347423B/es active IP Right Grant
- 2011-07-08 PT PT117303149T patent/PT2590955T/pt unknown
- 2011-07-08 PL PL11730314T patent/PL2590955T3/pl unknown
- 2011-07-08 EP EP16191215.9A patent/EP3144312A1/en not_active Withdrawn
- 2011-07-08 RU RU2016140266A patent/RU2016140266A/ru unknown
- 2011-07-08 KR KR1020137003334A patent/KR101889695B1/ko active IP Right Grant
- 2011-07-08 SG SG2013000625A patent/SG186926A1/en unknown
- 2011-07-08 NZ NZ605486A patent/NZ605486A/en unknown
- 2011-07-08 UY UY0001033497A patent/UY33497A/es not_active Application Discontinuation
-
2012
- 2012-12-31 IL IL224049A patent/IL224049B/en active IP Right Grant
-
2013
- 2013-01-07 ZA ZA2013/00153A patent/ZA201300153B/en unknown
- 2013-10-16 HK HK13111651.2A patent/HK1184153A1/zh unknown
-
2016
- 2016-08-05 US US15/230,063 patent/US9951084B2/en active Active
-
2018
- 2018-11-13 US US16/189,062 patent/US10807991B2/en active Active
-
2020
- 2020-08-31 US US17/007,359 patent/US11427598B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ605486A (en) | Spiro-cyclic amine derivatives as s1p modulators | |
| PH12015502001A1 (en) | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| MX366855B (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
| UA106692C2 (uk) | ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ | |
| IN2015DN00957A (es) | ||
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| MX345830B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
| MY167396A (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| JO3569B1 (ar) | مركبات بروبيل حلقي متحد مع ثيازين-2-أمين كمثبطات انزيم بيتا سكريتاز وطرق استخدامها | |
| MX2012010400A (es) | Inhibidores de fosfodiesterasa 10 (pde10) y composiciones y metodos relacionados. | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| NZ605491A (en) | Fused heterocyclic derivatives as s1p modulators | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| WO2012044562A3 (en) | Pyrazolopyrimidine pde10 inhibitors | |
| WO2012054366A3 (en) | Substituted amino-triazolyl pde10 inhibitors | |
| MX2016003422A (es) | Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen. | |
| EP2542085A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER | |
| IN2014DN09826A (es) | ||
| PH12014502780A1 (en) | Azetidine and piperidine compounds useful as pde10 inhibitors | |
| GEP20156227B (en) | Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same | |
| MX2014002343A (es) | Inhibidores de parp. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S23 | Proceedings under section 23: mention of inventor as such in patent |
Free format text: INVENTOR ADRIAN D. HOBSON ADDED Effective date: 20140205 |
|
| ASS | Change of ownership |
Owner name: ABBV, NL Effective date: 20140403 Owner name: ABBVIE INC., US Effective date: 20140403 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2016 BY THOMSON REUTERS Effective date: 20150620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2017 BY THOMSON REUTERS Effective date: 20160610 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2018 BY THOMSON REUTERS Effective date: 20170621 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2019 BY THOMSON REUTERS Effective date: 20180622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2020 BY COMPUTER PACKAGES INC Effective date: 20190618 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2021 BY COMPUTER PACKAGES INC Effective date: 20200618 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2022 BY COMPUTER PACKAGES INC Effective date: 20210617 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2023 BY COMPUTER PACKAGES INC Effective date: 20220618 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2024 BY THOMSON REUTERS Effective date: 20231101 |